quote from the news release: "I am excited to be part of this evolution in patient treatment as we advance the Cell Pouch cell therapy approach towards a functional cure for diabetes.”

This comes from today's press release put out by Sernova (SVA:TSXV)

Its very early.  Too early to claim a functional cure.  5 out of 7patients treated

https://www.thenewswire.com/press-releases/1LpMFDOv9-sernova-principal-investigator-presents-additional-positive-preliminary-safety-and-efficacy-data-from-ongoing-us-phase-i-ii-cell-pouch-clinical-trial-for-type-1-diabetes.html

So, how would this translate to our target market:  patients with ACS and T2D?  Any thoughts?

I nibbled on some